ProfileGDS5678 / 1450886_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 50% 54% 42% 72% 45% 38% 44% 60% 41% 45% 45% 44% 43% 64% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.2606650
GSM967853U87-EV human glioblastoma xenograft - Control 23.341354
GSM967854U87-EV human glioblastoma xenograft - Control 32.9847542
GSM967855U87-EV human glioblastoma xenograft - Control 44.6903172
GSM967856U87-EV human glioblastoma xenograft - Control 52.9980145
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9599738
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.095344
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6168360
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9208341
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.0336645
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0557645
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9847344
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0084343
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.8601864